ArticleAmerican journal of translational research2026
Hypotension incidence comparison between remimazolam and propofol in hypertensive patients undergoing spinal surgery.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to compare the incidence of hypotension between remimazolam and propofol in hypertensive patients undergoing spinal surgery.
methodsWe conducted a retrospective analysis of 194 hypertensive patients who received either remimazolam (n=99) or propofol (n=95) as the primary anesthetic during spinal surgery under general anesthesia. Hemodynamic parameters and bispectral index (BIS) were continuously monitored. The primary outcome was the incidence of intraoperative hypotension, defined as a mean arterial pressure (MAP) below 80% of baseline within 13 minutes of drug administration. Severe hypotension was defined as MAP below 70% of baseline. Postoperative adverse events, including postoperative nausea and vomiting (PONV), injection pain, dizziness, delirium, and hypoxemia, were also recorded.
resultsThe incidence of hypotension was significantly lower in the remimazolam group compared to the propofol group (82.83% vs. 93.68%, P=0.019). The remimazolam group demonstrated more stable MAP at key time points (5-12 minutes post-induction) and a lower incidence of PONV (15.15% vs. 29.47%, P=0.016) and injection pain (2.02% vs. 26.32%, P<0.001). Multivariate logistic regression identified remimazolam as an independent protective factor against hypotension (odds ratio [OR] =0.435, 95% confidence interval [CI]: 0.210-0.901, P=0.025).
conclusionsFor hypertensive patients undergoing spinal surgery, remimazolam is associated with a significantly lower risk of intraoperative hypotension and fewer adverse events compared to propofol, suggesting it may be a safer anesthetic option for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.